Thiazide diuretics and the initiation of anti-gout therapy (Q34742848)

4 August 2017

Thiazide diuretics and the initiation of anti-gout therapy (English)

1 reference

4 August 2017

4

Glynn RJ

1 reference

4 August 2017

1

Gurwitz JH

1 reference

4 August 2017

3

Bohn RL

1 reference

4 August 2017

7

Avorn J

1 reference

4 August 2017

6

Mogun H

1 reference

4 August 2017

Kalish SC

2

1 reference

PubMed ID

9291881

4 August 2017

Monane M

series ordinal

5

1 reference

4 August 2017

1 August 1997

1 reference

Journal of Clinical Epidemiology

4 August 2017

1 reference

4 August 2017

50

1 reference

4 August 2017

8

1 reference

4 August 2017

953-959

1 reference

Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Factors affecting urate excretion following diuretic administration in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Changes in renal urate handling after prolonged thiazide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Epidemiology of gout and hyperuricemia. A long-term population study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Treatment for glaucoma: adherence by the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Reserpine and breast cancer. A community-based longitudinal study of 2,000 hypertensive women

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Asymptomatic Hyperuricemia: The Case for Conservative Management

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Acute gouty arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Hepatitis associated with allopurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Prevention and management of gout

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900101-7

7 January 2021

10.1016/S0895-4356(97)00101-7

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

9291881